Doç. Dr. MURAT SARI

1. YAU-RCC spotlight: dual VEGF/EGFR blockade shows promise for reshaping the treatment of papillary RCC in hereditary leiomyomatosis and renal cell cancer syndrome

ERDEM S., SARI M., Marandino L., Flippot R., Amparore D., Campi R.

Minerva urology and nephrology , cilt.77, sa.5, ss.587-591, 2025 (SCI-Expanded)

2. Clinical and Demographic Features in Malignant Peritoneal Mesothelioma: Treatment Approaches and Factors Affecting Survival

SEVER N., Yildirim S., Gürbüz A. F., Karakaş Kiliç D., Zeynelgil E., Altintaş Y. E., et al.

Journal of Oncological Science , cilt.11, sa.2, ss.104-111, 2025 (Scopus)

3. Clinicopathological Features and Survival Outcomes of Colorectal Cancer Patients Under 40 Years: A 20-Years Single-Center Experience

Kaan A., Demircan N. C., ÖZGÜR S. Ş., AKYOL T. B., majıdova n., Kocaaslan E., et al.

Uluslararası Hematoloji-Onkoloji Dergisi , cilt.35, sa.2, ss.104-111, 2025 (SCI-Expanded, Scopus, TRDizin)

4. “Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?

Yaşar S., Kadıoğlu A., Akyildiz A., SEVER N., Büyükbayram M. E., BİLİCİ M., et al.

Medicina (Lithuania) , cilt.61, sa.6, 2025 (SCI-Expanded)

5. Evaluation of Pancreatic Atrophy in Patients with Hepatocellular Carcinoma Receiving Sorafenib Treatment

Kaan A., Zengin G., majıdova n., SEVER N., Ergelen R., Köstek O., et al.

Eurasian Journal of Medical Investigation , cilt.9, sa.1, ss.29-35, 2025 (Hakemli Dergi)

6. Kas-İnvaziv mesane kanserinde neoadjuvan ve adjuvan kemoterapinin sağkalım üzerine etkinliği: Çok merkezli çalışma

majıdova n., Öztürk A. E., Çolak R., yalıcı ö., İÇLİ M. C., KÖKSAL B., et al.

Turkish Journal of Clinics and Laboratory , cilt.16, sa.1, ss.123-130, 2025 (Hakemli Dergi)

7. Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group

SEVER N., ŞİMŞEK F., Onur İ. D., Arvas H., GULIYEV T., Şakalar T., et al.

Journal of Clinical Medicine , cilt.14, sa.6, 2025 (SCI-Expanded)

8. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

Tural D., Özkan O., Eylemer Mocan E., Kapar C., YASLIKAYA Ş., TATLI A. M., et al.

Future Oncology , cilt.21, sa.27, ss.3499-3505, 2025 (SCI-Expanded, Scopus)

9. The Effect of PET/CT SUV max Value on Anti-EGFR Treatment Response in Lung Adenocarcinoma

Ercelep O., Isik S., ERCAN E., KÖSTEK O., Bayoglu V., Celebi A., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.35, sa.3, ss.159-165, 2025 (SCI-Expanded, Scopus)

10. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis

SEVER N., Yıldırım S., Gurbuz A. F., Karakaş Kılıç D., Zeynelgil E., Altintaş Y. E., et al.

Medicina (Lithuania) , cilt.61, sa.1, 2025 (SCI-Expanded)

11. HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: A case report

Güren A. K., KOCAASLAN E., AĞYOL Y., Majidova N., Sever N., EREL P., et al.

Anti-Cancer Drugs , cilt.35, sa.8, ss.769-773, 2024 (SCI-Expanded)

12. The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma

Arak H., Erkiliç S., YASLIKAYA Ş., EYLEMER MOCAN E., Aktaş G., Özdemir M., et al.

Journal of immunotherapy (Hagerstown, Md. : 1997) , cilt.47, sa.5, ss.182-189, 2024 (SCI-Expanded)

13. Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience

Majidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.34, sa.1, ss.20-27, 2024 (SCI-Expanded, Scopus, TRDizin)

14. The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients

Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., et al.

Turkish Journal of Medical Sciences , cilt.54, sa.1, ss.229-238, 2024 (SCI-Expanded)

15. Systemic Inflammation Response Index and Pan-Immune-Inflammation Value: Prognostic Significance in Metastatic Melanoma

Majidova N., Kircali M. F., Güren A. K., Sever N., KOCAASLAN E., AĞYOL Y., et al.

Journal of Oncological Science , cilt.10, sa.3, ss.144-149, 2024 (Scopus)

16. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

KÖSTEK O., DEMİREL A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.

Journal of Chemotherapy , cilt.36, sa.7, ss.613-621, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

17. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

BAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., et al.

Journal of Clinical Medicine , cilt.12, sa.19, 2023 (SCI-Expanded)

18. The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study

ÇALIŞKAN YILDIRIM E., ATAĞ E., Coban E., Umit Unal O., Celebi A., Keser M., et al.

Breast , cilt.70, ss.56-62, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma

19. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib

ARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.53-61, 2023 (Scopus)

Yayınlar & Eserler